Aptamer Group plc (LSE:APTA)has raisedAUD 3.8 millionbefore expenses through a placing of ordinary shares to new and existing shareholders. The capital raise includes a firm placing and a conditional placing of a combined666,666,666 new Ordinary Sharesat an issue price of 0.3 pence per share, …
Avacta Therapeutics plc (LSE:AVCT),a UK-based clinical-stage life sciences company, provided a business update ahead of its 2025 Annual General Meeting, outlining recent progress across its oncology pipeline and key corporate developments.
Spire Healthcare Group plc (LSE:SPI), one of the UK's largest independent healthcare providers, has been rated aBUYby both Berenberg and Panmure Liberum, with analysts forecastingup to 31.34% upsidefrom its current share price ofGBp 217.0. Target prices ofGBp 280 and GBp 285reflect market confidence in …
Avacta Therapeutics plc (LSE:AVCT), a UK-based life sciences company specialising in oncology therapeutics, has released its unaudited preliminary financial and operational results for the full year ended December 31, 2024 (FY24). The company marked a pivotal year in its transformation into a pure-play oncology …
Dr. Martens plc (LSE:DOCS)has reported its preliminary results for the 52 weeks ending 30 March 2025, with management declaring the year as one of significant strategic progress despite a drop in headline financials. The company now expects to return to profit growth in FY26 …
hVIVO plc (LSE:HVO)is a UK-based contract research organisation specialising in human challenge clinical trials. The company also offers laboratory and early-phase clinical trial services through its subsidiaries, including CRS and Venn.
ANGLE plc (LSE:AGL),a UK-based liquid biopsy company specializing in circulating tumour cell (CTC) solutions, has released its audited preliminary financial results for the year ended 31 December 2024. The company reported a reduction in operating loss alongside a revenue increase, following operational restructuring and …
Poolbeg Pharma PLC(LSE:POLB) has achieved a major regulatory milestone in the United States, announcing that theFood and Drug Administration (FDA)has grantedOrphan Drug Designation (ODD)for its lead candidatePOLB 001, an oral therapy developed toprevent cytokine release syndrome (CRS).
Poolbeg Pharma PLC (LSE:POLB), a clinical-stage biopharmaceutical company listed on the London Stock Exchange, has announced the successful completion of an upsized and oversubscribed share offering that raised approximately £4.865 million in gross proceeds. The fundraising extends its operational runway through to 2027.
IXICO PLC (LSE:IXI, OTC:PHYOF)has released its first-half performance for the six months ending 31 March 2025, with the neuroscience imaging specialist saying it remains on course to meet or exceed its full-year expectations. The company credited its strategic focus on commercial and technological execution …